The value of healthcare M&A in H1 surpassed pre-pandemic levels -
Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
7/30/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery -
The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more
The healthcare sector (incorporating pharma, medical and biotech) has seen M&A valued at US$256.5 billion across 645 deals in 2019. This is a decrease of 9 percent by volume, but an increase of 121 percent by value....more
The need to replenish intellectual property has pushed the pharma industry to the highest-performing sector by M&A value.
In the pharmaceuticals, medical and biotech sector, deal value in the first half of the year was up...more
Although deal volume and value in the pharma, medical and biotech sector fell in 2018, down by 3 percent to 580 deals and 27 percent to US$111.8 billion respectively, pharma companies have invested aggressively in strategic...more